Endocrine Abstracts

Methodology: Between Jan’20 to Jan’21, 364 patients on thyroid replacement therapy were included in the study and analysed retrospectively. They were divided in 2 groups. T4 group (189 on levothyroxine therapy {T4} therapy) & T3 group (175 on levothyroxine/liothyronine combination therapy {T3/T4}. Hypothyroidism was defined as TSH >4.2 mIU/ml on > 2 occasions > 2 weeks apart irrespective of their thyroid antibody (anti-TPO Ab) status or TSH > 4.2 ...

Aim: To asses the role of Liothyronine (T3)+Levothyroxine combination (T4) therapy in 70 overweight/obese patients with Thyrotropin Stimulating Hormone (TSH mIU/ml) between 2.5-5 who were unable to lose weight. Methods: Between Jan’ 20 - Jan’ 21, 70 overweight/obese patients with TSH 2.5 -5 performed on ± 2 occasions ± 4 weeks apart were retrospectively analyzed. 24% {17/70} had TSH 2.5-2.99, 37% {26/70} had TSH 3-3.99 & 39% {27/70} h...

We describe four female patients with T2DM, presenting with nocturnal dizziness (ND), low capillary blood glucose & low BP, that was partially relieved with oral glucose & salt water. C1: MB 66 years, on background of hypertension (HT, valsartan + hydrochlorthiazide (HCT) + amlodipine (AM) ), hypothyroidism (T4D) (levothyroxine 700 mg/week) & IHD (pEF) presented, 3 years into her diagnosis, A1c 52 mmol/mol, with unsteady gait, frequent falls (normal-neurolo...

Aim: To asses the role of oral semaglutide (Sm) on weight & cardiac biomarkers (CB) in 69 patients with hypothyroidism optimally controlled using Liothyronine (T3)+Levothyroxine combination (T4) therapy (T3/T4).Methods: Between January 2022 and March 2022, 69 hypothyroid patients, who were treated using T3/T4 while on regular follow up, initiated Sm with the intention of weight loss and were retrospectively analysed....